Secretome Proteomics for VHL Tumor Biomarker Discovery
Secretome Proteomics for VHL Tumor Biomarker Discovery
批准号:
7740299
负责人:
YUZURU SHIIO
金额:
$16.33万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2011-07-31
关键词:
AccountingAffectAllelesApplications GrantsBiological MarkersCancer DetectionCell LineCellsCodeConventional (Clear Cell) Renal Cell CarcinomaCystDataData SetDiagnosisEarly DiagnosisEpithelial CellsFamily memberHereditary Neoplastic SyndromesInterventionIsotopically-Coded Affinity TaggingKidneyLuciferasesMalignant Epithelial CellMalignant NeoplasmsMethodsModelingMonitorMutateMutationNIH Program AnnouncementsNervous system structureOncogene ProteinsPatientsPeptidesPheochromocytomaPrincipal InvestigatorProtein SecretionProteinsProteomeProteomicsRNA InterferenceRenal Cell CarcinomaRenal carcinomaRetinaSamplingSerumSomatic MutationSystemTechnologyTestingTumor MarkersTumor Suppressor ProteinsVHL mutationValidationVascular Endothelial Growth FactorsVon Hippel-Lindau Syndromeassay developmentbasecancer cellcandidate markercandidate validationhemangioblastomamutation carrierneoplastic cellnovelnumb proteinoutcome forecastpre-clinicalprogramspublic health relevanceresearch studyresponsescale upstable isotopetumorvector
中文摘要
描述(由申请人提供):由于血清蛋白质组的异常复杂性,通过直接的血清蛋白质组学分析发现肿瘤生物标志物仍然是一个挑战。作为替代方案,本应用程序建议分析培养中肿瘤细胞分泌的蛋白质,然后使用来自肿瘤患者和健康对照者的血清样本验证这些候选肿瘤标志物。中心假设是肿瘤生物标志物可以被识别为在失去肿瘤抑制因子时显示增强分泌的蛋白质。本应用的目的是使用von Hippel-Lindau (VHL)肿瘤抑制因子作为模型案例来验证这一假设:它旨在识别VHL肿瘤生物标志物,即在VHL肿瘤抑制因子缺失时显示分泌增加的蛋白质。VHL疾病是一种遗传性癌症综合征,以透明细胞肾癌、神经系统血管母细胞瘤和肾上腺嗜铬细胞瘤为特征。VHL患者携带一个野生型VHL等位基因和一个灭活型VHL等位基因。这些患者的肿瘤和囊肿是由剩余的野生型等位基因的体细胞突变引起的。双等位基因VHL失活在散发性透明细胞肾癌和血管母细胞瘤中也很常见。目前,VHL疾病或肾细胞癌没有有效的血清肿瘤生物标志物。该生物标志物有助于VHL突变携带者的监测和临床前干预,有助于早期发现散发性肾癌。采用定量蛋白质组学技术ICAT(同位素编码亲和标签),对一株VHL-null肾癌细胞株786-O及其重新引入vhl的衍生物的蛋白质分泌进行了初步的小规模分析。该分析确定了许多蛋白质在VHL丧失时显示出分泌增强,包括血管内皮生长因子(VEGF),其在VHL疾病患者中显示出显著升高的血清水平。在这些初步数据的指导下,本应用程序追求两个特定目标:1)使用3种不同的细胞系统扩大和扩展初步分析,全面鉴定候选VHL肿瘤生物标志物;2)使用VHL疾病患者和健康对照者的血清样本验证这些候选标志物,并确定这些验证过的标志物在这些患者和对照者中的绝对血清浓度范围。公共卫生相关性:本项目拟通过分析VHL肿瘤抑制因子缺失时分泌的蛋白,发现VHL突变肿瘤的血清生物标志物,这将促进VHL突变携带者的监测和临床前干预,以及早期发现散发性肾细胞癌。此外,本项目开发的基于分泌组蛋白组学的癌症生物标志物发现方法将广泛适用于其他肿瘤抑制因子和癌蛋白,促进许多有用的癌症生物标志物的鉴定。
英文摘要
DESCRIPTION (provided by applicant): Because of the extraordinary complexity of the serum proteome, tumor biomarker discovery by direct proteomic analysis of blood serum continues to be a challenge. As an alternative, this application proposes to analyze proteins secreted from tumor cells in culture and later validate these candidate tumor markers using serum samples from tumor patients and healthy controls. The central hypothesis is that tumor biomarkers can be identified as proteins displaying enhanced secretion upon loss of a tumor suppressor. The objective of the present application is to test this hypothesis using the von Hippel-Lindau (VHL) tumor suppressor as a model case: it is directed towards identifying the VHL tumor biomarkers as proteins displaying increased secretion upon loss of the VHL tumor suppressor. VHL disease is a hereditary cancer syndrome characterized by clear cell renal carcinomas, hemangioblastomas of the nervous system, and adrenal pheochromocytomas. Patients with VHL disease harbor one wild-type VHL allele and one inactivated VHL allele. Tumors and cysts in these patients arise by somatic mutation of the remaining wild-type allele. Biallelic VHL inactivation is also common in sporadic clear cell renal carcinomas and hemangioblastomas Currently, there is no effective serum tumor biomarker for the VHL disease or renal cell carcinomas. Such biomarker would facilitate the monitoring and pre-clinical intervention of VHL mutation carriers and early detection of sporadic renal carcinomas. Employing a quantitative proteomics technology, ICAT (isotope-coded affinity tag), a preliminary small- scale analysis of protein secretion from a VHL-null renal carcinoma cell line, 786-O, and its VHL-reintroduced derivative was carried out. This analysis identified a number of proteins that display enhanced secretion upon VHL loss, including Vascular Endothelial Growth Factor (VEGF) which showed significantly elevated serum levels in VHL disease patients. Guided by these preliminary data, this application pursues two specific aims: 1) scale-up and extend the preliminary analysis using 3 different cell systems and comprehensively identify candidate VHL tumor biomarkers and 2) validate these candidate markers using serum samples from VHL disease patients and healthy controls and also determine the absolute serum concentration ranges of the validated markers in these patients and controls. PUBLIC HEALTH RELEVANCE: By analyzing proteins secreted upon loss of the VHL tumor suppressor, the proposed project discovers serum biomarkers for VHL-mutated tumors, which will advance the monitoring and pre- clinical intervention of VHL mutation carriers as well as early detection of sporadic renal cell carcinomas. Furthermore, secretome proteomics-based approach for cancer biomarker discovery developed by this project will be widely applicable to other tumor suppressors and oncoproteins, facilitating the identification of many useful cancer biomarkers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of the receptor complex and the cofactors in IGSF10 signaling
-
批准号:10728450
-
项目类别:
-
资助金额:$35.46万
-
财政年份:2023
-
负责人:YUZURU SHIIO
-
依托单位:
A novel oncogenic driver in Ewing sarcoma
-
批准号:9321922
-
项目类别:
-
资助金额:$16.58万
-
财政年份:2016
-
负责人:YUZURU SHIIO
-
依托单位:
A novel oncogenic driver in Ewing sarcoma
-
批准号:9179478
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2016
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7500280
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Quantitative Proteomic Analysis of the Secretory Pattern of Senescent Cells
-
批准号:7187525
-
项目类别:
-
资助金额:$14.97万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7314758
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7669079
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Quantitative Proteomic Analysis of the Secretory Pattern of Senescent Cells
-
批准号:7348336
-
项目类别:
-
资助金额:$14.67万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:8100114
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
Analysis of the VHL-HIF hydroxylase pathway
-
批准号:7896480
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2007
-
负责人:YUZURU SHIIO
-
依托单位:
海外基金